
Boehringer Ingelheim puts China strategy into action with SBP deal
Boehringer Ingelheim and China’s SBP Group have entered a strategic multi-programme agreement with to advance potential cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies. Building on the companies’ existing collaboration in oncology, the agreement will bring together SBP Group’s platforms and early-development capabilities with Boehringer Ingelheim’s… Read More












